MSD makes licence agreement with Hengrui Pharma for Lp(...
MSD has entered an exclusive licence agreement with Hengrui Pharma for the oral ...
Character Biosciences gains $93m for precision eye dise...
Character Biosciences has raised $93m in an oversubscribed Series B funding roun...
Cassava ends simufilam Alzheimer’s programme after seco...
While Cassava is stopping investigations into simufilam in Alzheimer’s disease, ...